49 results on '"Bychkovsky, Brittany L."'
Search Results
2. Incidence of endometrial cancer in BRCA mutation carriers
3. HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome
4. Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
5. Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
6. Inequities in referrals to a breast cancer risk assessment and prevention clinic: a mixed methods study
7. Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception
8. Cancer burden in individuals with single versus double pathogenic variants in cancer susceptibility genes
9. Screening MRI Does Not Increase Cancer Detection or Result in an Earlier Stage at Diagnosis for Patients with High-Risk Breast Lesions: A Propensity Score Analysis
10. TP53-associated early breast cancer: new observations from a large cohort.
11. Correction to: Pathogenic variants among females with breast cancer and a non‑breast cancer reveal opportunities for cancer interception
12. Cancer control in Latin America and the Caribbean: recent advances and opportunities to move forward
13. ASO Visual Abstract: Screening MRI Does Not Increase Cancer Detection or Result in Earlier Stage at Diagnosis in Patients with High-Risk Breast Lesions–A Propensity Score Analysis
14. Ductal Carcinoma In Situ
15. Cost-Effectiveness Studies in Oncology
16. Endometrial Cancer Risk Among Germline BRCA1/2 Pathogenic Variant Carriers: Review of Our Current Understanding and Next Steps
17. Breast Cancer Screening in High-risk Women During Pregnancy and Lactation
18. Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies
19. Imaging in the evaluation and follow-up of early and advanced breast cancer: When, why, and how often?
20. Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
21. Supplementary Figure from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
22. Are rare cancer survivors at elevated risk of subsequent new cancers?
23. Progress and remaining challenges for cancer control in Latin America and the Caribbean
24. Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care—Checking CHEK2
25. ASO Visual Abstract: Screening MRI Does Not Increase Cancer Detection or Result in Earlier Stage at Diagnosis in Patients with High-Risk Breast Lesions–A Propensity Score Analysis
26. Screening MRI Does Not Increase Cancer Detection or Result in an Earlier Stage at Diagnosis for Patients with High-Risk Breast Lesions: A Propensity Score Analysis
27. Challenges to effective cancer control in China, India, and Russia
28. Double jeopardy? A closer look at cancer histories of individuals with multiple germline pathogenic variants.
29. Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
30. Abstract P2-09-03: Pathogenic variants among female breast cancer patients with a subsequent cancer demonstrate preventable cancer burden
31. A Tribute to Dr Larissa Lee
32. Prevalence and spectrum of pathogenic variants among patients with multiple primary cancers evaluated by clinical characteristics
33. Older women’s experience with breast cancer treatment decisions
34. Cervical cancer control in Latin America: A call to action
35. Prevalence and spectrum of pathogenic variants among patients with multiple primary cancers.
36. Identification and management of pathogenic mutations in BRCA1, BRCA2, and PALB2 in a tumor-only genomic testing program.
37. Prevalence and spectrum of pathogenic variants among patients with multiple primary cancers evaluated by clinical characteristics.
38. Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials
39. Genomic landscape of de novo stage IV breast cancer.
40. Cancer Pathology Turnaround Time at Queen Elizabeth Central Hospital, the Largest Referral Center in Malawi for Oncology Patients
41. Systemic Therapies for Nonmetastatic Breast Cancer: The Role of Neoadjuvant and Adjuvant Chemotherapy and the Use of Endocrine Therapy
42. Compulsory Licenses for Cancer Drugs: Does Circumventing Patent Rights Improve Access to Oncology Medications?
43. Use and Yield of Baseline Imaging and Laboratory Testing in Stage II Breast Cancer
44. A description of a small cohort of Argentinian women presenting with cervical cancer (CC) highlighting the need for CC control in Latin America (LA).
45. Poor persistence with hormonal therapy among women with breast cancer
46. Cervical cancer control in Latin America: A call to action
47. TP53-associated early breast cancer: new observations from a large cohort.
48. Genotype matters: Personalized screening recommendations for germline CHEK2 variants.
49. Endometrial Cancer Risk Among Germline BRCA1 / 2 Pathogenic Variant Carriers: Review of Our Current Understanding and Next Steps.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.